Alfacalcidol prevents aromatase inhibitor (Letrozole)-induced bone mineral loss in young growing female rats

Journal of Endocrinology

Volumn 202, Issue 2, 2009, Pages 317-325

  Mohamed, Idris ^a   Yeh, James K ^a  

^a WINTHROP UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALFACALCIDOL; LETROZOLE; LUTEINIZING HORMONE; TESTOSTERONE; 1-HYDROXYCHOLECALCIFEROL; AROMATASE INHIBITOR; BONE DENSITY CONSERVATION AGENT; HYDROXYCOLECALCIFEROL; NITRILE; TRIAZOLE DERIVATIVE;

ANIMAL EXPERIMENT; ARTICLE; BODY HEIGHT; BODY WEIGHT; BONE DENSITY; BONE MASS; BONE MINERALIZATION; CONTROLLED STUDY; FEMALE; NONHUMAN; OSSIFICATION; OSTEOLYSIS; PRIORITY JOURNAL; RAT; RISK FACTOR; ANIMAL; BONE DEVELOPMENT; CHEMICALLY INDUCED DISORDER; DRUG EFFECT; DRUG POTENTIATION; FEMUR; SPRAGUE DAWLEY RAT;

ANIMALS; AROMATASE INHIBITORS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; BONE DEVELOPMENT; BONE RESORPTION; DRUG SYNERGISM; FEMALE; FEMUR; HYDROXYCHOLECALCIFEROLS; NITRILES; RATS; RATS, SPRAGUE-DAWLEY; TRIAZOLES;

EID: 70349251891     PISSN: 00220795     EISSN: 14796805     Source Type: Journal    
DOI: 10.1677/JOE-08-0532     Document Type: Article

References (55)

1. Abbaspour A, Takata S, Matsui Y, Katoh S, Takahashi M & Yasui N 2008 Continuous infusion of insulin-like growth factor-I into the epiphysis of the tibia. International Orthopaedics 32 395-402.
2. Albright F, Smith PH & Richardson AM 1941 Postmenopausal osteoporosis. Journal of the American Medical Association 116 2465-2474.
3. Bonjour JP 1998 Delayed puberty and peak bone mass. European Journal of Endocrinology 139 257-259.
4. Bord S, Horner A, Beavan S & Compston J 2001 Estrogen Receptors a and b are differentially expressed in developing human bone. Journal of Clinical Endocrinology and Metabolism 86 2309-2314.
5. 3 and BCI-210 suppress PTH secretion by bovine parathyroid cells. Nephrology, Dialysis, Transplantation 21 644-650.
6. Buzdar A 2003 Pharmacology and pharmacokinetics of the newer generation aromatase inhibitors. Clinical Cancer Research 9 468S-472S.
7. Buzdar A & Howell A 2001 Advances in aromatase inhibition clinical efficacy and tolerability in the treatment of breast cancer. Clinical Cancer Research 7 2620-2635.
8. Carani C, Qin K, Simoni M, Faustini-Fustini M, Serpente S, Boyd J & Korach KS 1997 Effect of testosterone and estradiol in aman with aromatase deficiency. New England Journal of Medicine 337 91-95.
9. Compston JE 2001 Sex steroids and bone. Physiological Reviews 81 419-447.
10. Dunkel L & Wickman S 2001 Treatment of delayed male puberty: efficacy of aromatase inhibition. Journal of Pediatric Endocrinology and Metabolism 14 1541-1546.
11. Van der Eerden BCJ, Karperien M & Wit JM 2003 Systemic and local regulation of the growth plate. Endocrine Reviews 24 782-801.
12. 3. Journal of Bone and Mineral Research 17 1498-1511.
13. Eshet R, Maor G, Ari TB, Eliezer MB, Gat-Yablonski G & Phillip M 2004 The aromatase inhibitor Letrozole increases espiphyseal growth plate height and tibial length in peripubertal male mice. Journal of Endocrinology 182 165-172.
14. Finkelstein JS, Neer RM, Biller BM, Crawford JD & Klibanski A 1992 Osteopenia in men with a history of delayed puberty. New England Journal of Medicine 326 600-604.
15. Fowlkes JL, Thrailkill KM, Liu L, Wahl EC, Bunn RC, Cockrell GE, Perrien DS, Aronson J & Lumpkin CK Jr 2006 Effects of systemic and local administration of recombinant human IGF-I (rhIGF-I) on de novo bone formation in an aged mouse model. Journal of Bone and Mineral Research 21 1359-1366.
16. Frost HM 2004 The Utah Paradigm of Skeletal Physiology, ch 3 and 4. Greece: International Society of Musculoskeletal and Neuronal Interactions.
17. Gasser JA, Green JR, Shen V, Ingold P, Rebmann A, Bhatnagar AS & Evans DB 2006 A single intravenous administration of zoledronic acid prevents the bone loss and mechanical compromise induced by aromatase inhibition in rats. Bone 39 787-795.
18. Goss PE, Qi S, Cheung AM, Hu H, Mendes M & Pritzker KP 2004 Effects of the steroidal aromatase inhibitor exemestane and the nonsteroidal aromatase inhibitor Letrozole on bone and lipid metabolism in ovariectomized rats. Clinical Cancer Research 10 5717-5723.
19. Grinspoon S, Baum H, Lee K, Anderson E, Herzog D & Klibanski A 1996 Effects of short-term recombinant human insulin-like growth factor I administration on bone turn over in osteopenic women with anorexia nervosa. Journal of Clinical Endocrinology and Metabolism 81 3864-3870.
20. Hefferan TE, Evans GL, Lotinun S, Zhang M, Morey-Holton E & Turner RT 2003 Effect of gender on bone turnover in adult rats during simulated weightlessness. Journal of Applied Physiology 95 1775-1780.
21. Heldring N, Pike A, Andersson S, Matthews J, Cheng G, Hartman J, Tujague M, Ström A, Treuter E, Warner M et al. 2007 Estrogen receptors: how do they signal and what are their targets. Physiological Reviews 87 905-931.
22. Iwamoto J, Seki A, Takeda T, Sato Y, Yamada H & Yeh JK 2006 Comparative therapeutic effects of alendronate and alfacalcidol on cancellous and cortical bone mass and mechanical properties in ovariectomized osteopenic rats. Journal of Nutritional Science and Vitaminology 52 1-8.
23. Iwamoto J, Seki A, Takeda T, Yamada H, Sato Y & Yeh JK 2007 Effects of alfacalcidol on cancellous and cortical bone mass in rats treated with glucocorticoid: a bone histomorphometry study. Journal of Nutritional Science and Vitaminology 53 191-197.
24. Iwamoto J, Takeda T, Matsumoto H, Sato Y & Yeh JK 2008 Beneficial effects of combined administration of alendronate and alfacalcidol on cancellous bone mass of the tibia in orchidectomized rats: a bone histomorphometry study. Journal of Nutritional Science and Vitaminology 54 11-17.
25. Jansson JO, Eden S & Isaksson O 1983 Sites of action of testosterone and estradiol on longitudinal bone growth. American Journal of Physiology. Endocrinology and Metabolism 244 135-140.
26. Jensen CH, Hansen M, Brandt J, Rasmussen HB, Jensen PB & Teisner B 1998 Quantification of the N-terminal propeptide of human procollagen type I (P1NP): comparison of ELISA and RIA with respect to different molecular forms. Clinica Chimica Acta 269 31-41.
27. Legato MJ 2003 Beyond women's health the new discipline of gender-specific medicine. Medical Clinics of North America 87 917-937.
28. Li M, Healy DR, Li Y, Simmons HA, Su M, JeeWS, Shen VW & Thompson DD 2004 Alfacalcidol prevents age-related bone loss and causes an atypical pattern of bone formation in aged male rats. Journal of Musculoskeletal and Neuronal Interactions 4 22-32.
29. MacGillivray MH, Morishima A, Conte F, Grumbach M & Smith EP 1998 Pediatric endocrinology update: an overview. The essential roles of estrogens in pubertal growth, epiphyseal fusion and bone turnover: lessons from mutations in the genes for aromatase and the estrogen receptor. Hormone Research 49 2-8.
30. Majima T, Komatsu Y, Shimatsu A, Satoh N, Fukao A, Ninomiya K, Matsumura T & Nakao K 2008 Efficacy of combined treatment with raloxifene and alfacalcidol on bone density and biochemical markers of bone turnover in postmenopausal osteoporosis. Endocrine Journal 55 127-134.
31. Maor G, Segev Y & Phillip M 1999 Testosterone stimulates insulin-like growth factor-1 and insulin-like growth factor-1 receptor gene expression in the mandibular condyle - a model of endochondral ossification. Endocrinology 140 1901-1910.
32. Meinel L, Zoidis E, Zapf J, Hassa P, Hottiger MO, Auer JA, Schneider R, Gander B, Luginbuehl V, Bettschart-Wolfisberger R et al. 2003 Localized insulin-like growth factor I delivery to enhance new bone formation. Bone 33 660-672.
33. Melkko J, Kauppila S, Niemi S, Risteli L, Haukipuro K, Jukkola A & Risteli J 1996 Immunoassay for intact aminoterminal propeptide of human type I procollagen. Clinical Chemistry 42 947-954.
34. Nilsson A, Isgaard J, Lindahl A, Dahlström A, Skottner A & Isaksson OG 1986 Regulation by growth hormone of number of chondrocytes containing IGF-I in rat growth plate. Science 233 571-574.
35. Nilsson S, Mäkelä S, Treuter E, Tujague M, Thomsen J, Andersson G, Enmark E, Pettersson K, Warner M & Gustafsson J 2001 Mechanisms of estrogen action. Physiological Reviews 81 1535-1565.
36. Nishikawa T, Ogawa S, Kogita K, Manabe N, Katsumata T, Nakamura K & Kawaguchi H 2000 Additive effects of combined treatment with etidronate and alfacalcidol on bone mass and mechanical properties in ovariectomized rats. Bone 27 647-664.
37. Nuti R, Bianchi G, Brandi ML, Caudarella R, D'Erasmo E, Fiore C, Isaia GC, Luisetto G, Muratore M, Oriente P et al. 2006 Superiority of alfacalcidol compared to vitamin D plus calcium in lumbar bone mineral density in postmenopausal osteoporosis. Rheumatology International 26 445-453.
38. Parfitt AM, Drezner MK, Glorieux FH, Kanis JA, Maluche H, Meunier PJ, Ott SM & Recker RR 1987 Bone histomorphometry: standardization of nomenclature, symbols, and units. Report of the ASBMR Histomorphometry Nomenclature Committee. Journal of Bone and Mineral Research 2 595-610.
39. Phillip M, Maor G, Assa S, Silbergeld A & Segev Y 2001 Testosterone stimulates growth of tibial epiphyseal growth plate and insulin-like growth factor-1 receptor abundance in hypophysectomized and castrated rats. Endocrine 16 1-6.
40. Riggs BL, Khosla S & Melton LJ III 2002 Sex steroids and the construction and conservation of the adult skeleton. Endocrine Reviews 23 279-302.
41. Ringe JD, Farahmand P, Schacht E & Rozehnal A 2007 Superiority of a combined treatment of alendronate and alfacalcidol compared to the combination of alendronate and plain vitamin D or alfacaocidol alone in established postmenopausal or male osteoporosis. Rheumatology International 27 425-434.
42. Rissanen JP, Suominen MI, Peng Z, Morko J, Rasi S, Risteli J & Halleen JM 2008 Short-term changes in serum P1NP predict long-term changes in trabecular bone in the rat ovariectomy model. Calcified Tissue International 82 155-161.
43. Schacht E, Richy F & Reginster JY 2005 The therapeutic effects of alfacalcidol on bone strength, muscle metabolism and prevention of falls and fractures. Journal of Musculoskeletal & Neuronal Interactions 5 273-284.
44. Shankar S & Hosking DJ 2006 Biochemical assessment of Paget's disease of bone. Journal of Bone and Mineral Research 21 P22-P27.
45. Shen CL, Wang P, Guerrieri J, Yeh JK & Wang JS 2008 Protective effect of green tea polyphenols on bone loss in middle-aged female rats. Osteoporosis International 19 979-990.
46. Shibata T, Shira-Ishi A, Sato T, Masaki T, Sasaki A, Masuda Y, Hishiya A, Ishikura N, Higashi S, Uchida Y et al. 2002 Vitamin D hormone inhibits osteoclastogenesis in vivo by decreasing the pool of osteoclast precursors in bone marrow. Journal of Bone and Mineral Research 17 622-629.
47. Shiraishi A, Higashi S, Ohkawa H, Kubodera N, Hirasawa T, Ezawa I, Ikeda K & Ogata E 1999 The advantage of alfacalcidol over vitamin D in the treatment of osteoporosis. Calcified Tissue International 65 311-316.
48. Shiraishi A, Takeda S, Masaki T, Higuchi Y, Uchiyama Y, Kubodera N, Sato K, Ikeda K, Nakamura T, Matsumoto Tet al. 2000 Alfacalcidol inhibits bone resorption and stimulates formation in an ovariectomized rat model of osteoporosis: distinct from estrogen. Journal of Bone and Mineral Research 15 770-779.
49. Shulman DI, Francis GL, Palmert MR & Eugster EA 2008 Use of aromatase inhibitors in children and adolescents with disorders of growth and adolescent development. Pediatrics 121 e975-e983.
50. Soliman AT, Al Khalaf F, Alhemaidi N, Al Ali M, Al Zyoud M & Yakoot K 2008 Linear growth in relation to the circulating concentrations of insulin-like growth factor I, parathyroid hormone, and 25-hydroxy vitamin D in children with nutritional rickets before and after treatment: endocrine adaptation to vitamin D deficiency. Metabolism 57 95-102.
51. Szabo A, Merke J, Beier E, Mall G & Ritz E 1989 1,25 (OH)2 Vitamin D3 inhibits parathyroid cell proliferation in experimental uremia. Kidney International 35 1049-1056.
52. Thurlimann B, Keshaviah A, Coates AS, Mouridsen H, Mauriac L, Forbes JF et al. 2005 Breast International Group (BIG) 1-98 Collaborative Group. A comparison of Letrozole and tamoxifen in postmenopausal women with early breast cancer. New England Journal of Medicine 353 2747-2757.
53. 3 on long bones of glucocorticoid-treated rats. Acta Anatomica 145 61-67.
54. Vanderschueren D, Vandenput L, Boonen S, Linberg MK, Bouillon R & Ohlsson C 2004 Androgens and bone. Endocrine Reviews 25 389-425.
55. Zung A, Phillip M, Chalew SA, Palese T, Kowarski AA & Zadik Z 1999 Testosterone effect on growth and growth mediators of the GH-IGF-I axis in the liver and epiphyseal growth plate of juvenile rats. Journal of Molecular Endocrinology 23 209-221.